The new oncology division will be run by Jannie Oosthuizen, previously head of Merck Human Health US, while the non-oncology ...

Merck is splitting its pharmaceutical business into two units, separating its oncology operations from its non-cancer drugs ...

The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

MSD will integrate clinical insights and genomic datasets from Mayo Clinic Platform, aggregating data in a secure environment.

The results indicate that safety in children under two years was consistent across both RSV seasons receiving Enflonsia.

Merck, known as MSD outside the U.S. and Canada, is restructuring its Human Health organization and appointing three new leaders.

CAMBRIDGE, England--(BUSINESS WIRE)--Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial ...

SUZHOU, China--(BUSINESS WIRE)--Evopoint Biosciences Co., Ltd.(“Evopoint”), a biopharmaceutical company focused on discovering and developing innovative and transformative medicines, announced today a ...

Drug giant MSD expects the imminent loss of patent exclusivity on diabetes drug Januvia and other medicines to hit harder ‍than analysts are projecting. The comapny on Tuesday ‍forecast 2026 sales and ...